Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP

Launched by UNIVERSITY OF COLOGNE · Jul 21, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at how effective a medication called caplacizumab is in treating patients with a condition known as acquired thrombotic thrombocytopenic purpura (aTTP). The goal is to see how well this treatment works in real-life situations, not just in controlled clinical settings. The researchers want to gather information that could help improve treatment strategies for patients with aTTP, making sure they get the best care possible while keeping treatment costs manageable.

To participate in this study, individuals must be at least 18 years old and have a confirmed diagnosis of an acute episode of aTTP. They should have also received at least one dose of caplacizumab. The study aims to include both men and women. Participants will be asked to provide written consent to take part. It’s important to know that individuals with a hereditary form of thrombotic thrombocytopenic purpura or those unable to give informed consent will not be eligible. If you join the trial, you can expect to help researchers better understand how to manage this condition, potentially leading to improved treatment options for everyone affected by aTTP.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed diagnosis of an acute episode of acquired thrombotic thrombocytopenic purpura
• • Treatment with at least one single dose of caplacizumab (10 mg i.v. or s.c.)
• • Male or female patients ≥ 18 years of age
• • signed written informed consent
• Exclusion Criteria:
• • Hereditary thrombotic thrombocytopenic purpura
• • disability to give informed consent